Annual report pursuant to Section 13 and 15(d)

Document and Entity Information

v3.24.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Feb. 29, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Trading Symbol ITRM    
Entity Registrant Name Iterum Therapeutics plc    
Entity Central Index Key 0001659323    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Document Financial Statement Error Correction [Flag] false    
Entity Interactive Data Current Yes    
Title of 12(b) Security Ordinary Shares, $0.01 par value per share    
Security Exchange Name NASDAQ    
Entity File Number 001-38503    
Entity Incorporation, State or Country Code L2    
Entity Tax Identification Number 98-1283148    
Entity Address, Address Line One Fitzwilliam Court    
Entity Address, Address Line Two 1st Floor    
Entity Address, Address Line Three Leeson Close    
Entity Address, City or Town Dublin 2    
Entity Address, Country IE    
Entity Address, Postal Zip Code Not applicable    
City Area Code +353    
Local Phone Number 1 669-4820    
Document Annual Report true    
Document Transition Report false    
Entity Common Stock, Shares Outstanding   16,426,784  
Auditor Firm ID 1116    
Auditor Name KPMG    
Auditor Location Dublin, Ireland    
Entity Public Float     $ 13.7
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

 

Part III of this Annual Report on Form 10-K incorporates by reference information from the definitive proxy statement for the Registrant’s 2024 Annual Meeting of Shareholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the Registrant’s fiscal year ended December 31, 2023.